BMO Capital Markets cut shares of Precision BioSciences (NASDAQ:DTIL – Get Rating) to a market perform rating in a report published on Monday, The Fly reports.
Separately, BTIG Research decreased their price target on shares of Precision BioSciences to $6.00 in a research note on Tuesday, November 15th.
Precision BioSciences Trading Up 2.1 %
Shares of DTIL stock opened at $0.93 on Monday. The company has a 50 day moving average of $1.19 and a 200-day moving average of $1.30. The company has a quick ratio of 3.34, a current ratio of 3.34 and a debt-to-equity ratio of 0.37. Precision BioSciences has a 12-month low of $0.90 and a 12-month high of $3.93. The firm has a market cap of $103.45 million, a P/E ratio of -0.66 and a beta of 1.45.
Institutional Inflows and Outflows
Precision BioSciences Company Profile
Precision BioSciences, Inc is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases.
- Get a free copy of the StockNews.com research report on Precision BioSciences (DTIL)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.